Effector Therapeutics Inc (EFTR)vsBeiGene, Ltd. (ONC)
EFTR
Effector Therapeutics Inc
$0.00
0.00%
HEALTHCARE · Cap: $2,352
ONC
BeiGene, Ltd.
$346.51
+1.38%
HEALTHCARE · Cap: $40.53B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 907895% more annual revenue ($6.13B vs $675,000). ONC leads profitability with a 10.7% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 64/100 (C+).
EFTR
Avoid34
out of 100
Grade: F
ONC
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EFTR.
Margin of Safety
+80.1%
Fair Value
$1767.21
Current Price
$346.51
$1420.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 117.0% year-over-year
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 29.6% year-over-year
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : EFTR
The strongest argument for EFTR centers on Price/Book, Revenue Growth. Revenue growth of 117.0% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 29.6% demonstrates continued momentum. PEG of 0.77 suggests the stock is reasonably priced for its growth.
Bear Case : EFTR
The primary concerns for EFTR are EPS Growth, Market Cap, Profit Margin.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 64.1x leaves little room for execution misses.
Key Dynamics to Monitor
EFTR profiles as a hypergrowth stock while ONC is a growth play — different risk/reward profiles.
EFTR carries more volatility with a beta of 2.42 — expect wider price swings.
EFTR is growing revenue faster at 117.0% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (64/100 vs 34/100) and 29.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Effector Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Effector Therapeutics Inc (EFTR) is a clinical-stage biopharmaceutical company dedicated to redefining cancer treatment through the innovative modulation of RNA translation to selectively target tumor growth. With a robust pipeline of small molecule therapies, the company is strategically positioned to address critical unmet needs within oncology. Focused on advancing precision medicine, Effector Therapeutics aims to improve treatment outcomes and enhance the quality of life for cancer patients, all while navigating the dynamic landscape of biotechnology innovation.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?